• 1.1 To determine the long-term efficacy and safety of imatinib in patients with CML treated with standard dose outside of the setting of a clinical trial [ Time Frame: June 2012 ] [ Designated as safety issue: No ]
  

• 1.2. To determine the incidence of chromosomal abnormalities in Ph-negative metaphases associated with treatment with imatinib in patients with CML treated with standard dose outside of the setting of a clinical trial [ Time Frame: June 2012 ] [ Designated as safety issue: No ]
  
• 1.3. To determine the outcome of conception and pregnancy during treatment with imatinib in patients with CML [ Time Frame: June 2012 ] [ Designated as safety issue: No ]
  
• 1.4. To investigate the factors associated with response and failure to treatment with imatinib in patients with CML treated with standard dose outside of the setting of a clinical trial [ Time Frame: June 2012 ] [ Designated as safety issue: No ]
  
• 1.5. To investigate the occurrence of long-term adverse events and late-complications associated with imatinib therapy in patients with CML treated outside the setting of a clinical trial. [ Time Frame: June 2012 ] [ Designated as safety issue: No ]
  
• 1.6. To investigate the effect of treatment interruptions and treatment discontinuation in the rate and durability of response to imatinib [ Time Frame: June 2012 ] [ Designated as safety issue: No ]
  

PATIENT POPULATION:

All patients with CML in any phase of the disease (chronic, accelerated or blast phase) that has received treatment with imatinib not on an MDACC clinical trial regardless of prior treatment history, and has had at least one clinic visit at MDACC will be eligible.

STUDY PLAN:

The following information will be collected:

• Demographic information including age, gender, ethnicity, education, and work history.
• All laboratory values obtained at MDACC or other institutions, including CBC, blood chemistries, electrolytes, bone marrow aspirations and biopsies, cytogenetic analyses, FISH, and PCR.
• Treatment history including starting and stopping dates, doses, treatment interruptions, dose changes and reasons for dose modifications.
• Information about toxicity including type, grade, dates of onset and resolution, interventions to manage toxicity, and sequelae.
• Information regarding pregnancy or conception during imatinib therapy for both male and female patients, including dates of pregnancy, outcome of pregnancy, interventions during pregnancy, management of CML during pregnancy, complications during pregnancy, status of the product, condition of the born child, and information on lactation.

This information will be reviewed from the documents received as part of the routine communication with the local oncologist or from the studies obtained at MDACC.

There will be no treatment changes or recommendations as a result of this study. This study will be strictly limited to review of charts. Patients will continue their treatment as recommended by their local oncologist and treating physician at MDACC.

These results will be compared to similar patients treated with imatinib in the context of clinical trials both from published literature and from studies conducted at MDACC. The response rates, duration of response, toxicity, dose intensity, and rate of transformation will be compared.

Investigators will review data from July 1, 1998 to October 31, 2008.

SAMPLE SIZE:

Approximately 850 charts will be reviewed.